B. Mahé

P. Chevallier, M. Béné, P. Moreau, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/−R) is an effective treatment with low toxicity in Hodgkin’s and non-Hodgkin’s lymphomas

P. Chevallier, P. Moreau, A. Moreau, 2017, Annals of Hematology.

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience

P. Chevallier, P. Moreau, C. Leux, 2016, Annals of Hematology.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

P. Chevallier, M. Mohty, M. Béné, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Impact of high-dose chemotherapy followed by auto-SCT for positive interim [18F] FDG-PET diffuse large B-cell lymphoma patients

M. Mohty, P. Moreau, A. Moreau, 2011, Bone Marrow Transplantation.

Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies.

R. Gressin, E. Deconinck, P. Colombat, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

P. Chevallier, P. Moreau, H. Avet-Loiseau, 2005, Leukemia research.

Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression

P. Chevallier, J. Delaunay, B. Mahé, 2008, International journal of hematology.

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

A. Alavi, M. Czuczman, F. Kraeber-Bodéré, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

P. Chevallier, M. Mohty, M. Béné, 2016, Seminars in hematology.

Long-term results (12 years) of high-dose therapy in 127 patients with de novo multiple myeloma

R. Bataille, P. Moreau, B. Mahé, 2002, Leukemia.

Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamide

P. Chevallier, M. Béné, P. Moreau, 2020, Annals of Hematology.

Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide

P. Chevallier, M. Béné, P. Moreau, 2020, Acta oncologica.

Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study

P. Moreau, A. Moreau, B. Dupas, 1998, Bone Marrow Transplantation.

Long‐term outcome of monoclonal (type 1) cryoglobulinemia

B. Grosbois, O. Decaux, P. Jégo, 2014, American journal of hematology.

Acquired von Willebrand Syndrome Associated With Monoclonal Gammopathy: A Single-Center Study of 36 Patients

M. Trossaërt, B. Mahé, M. Hamidou, 2011, Medicine.

Front-line high-dose therapy with autologous stem cell transplantation for high risk Hodgkin's disease: comparison with combined-modality therapy

P. Moreau, N. Ifrah, P. Colombat, 2002, Bone Marrow Transplantation.

Early intensive therapy with autotransplantation for high-risk Hodgkin's disease.

P. Moreau, B. Dupas, B. Mahé, 1993, Leukemia & lymphoma.

lymphoma patients: results of the GELA-GOELAMS FL2000 study Rituximab combined with chemotherapy and interferon in follicular

J. Rossi, G. Salles, R. Bouabdallah, 2013 .

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

P. Chevallier, M. Béné, P. Moreau, 2019, Cytokine.

Mixed leukocyte culture reactivity, HLA-DP typing and GVHD.

P. Moreau, B. Mahé, A. Cesbron, 1993, Bone marrow transplantation.

Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.

M. Bonneville, M. Devilder, H. Vié, 1993, The Journal of clinical investigation.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation

P. Chevallier, M. Mohty, P. Moreau, 2012, Bone Marrow Transplantation.

Increased rituximab exposure does not improve response and outcome of patients with chronic lymphocytic leukemia after fludarabine, cyclophosphamide, rituximab. A French Innovative Leukemia Organization (FILO) study

P. Feugier, S. Leprêtre, R. Letestu, 2018, Haematologica.

Is ASCT With TBI Superior to ASCT Without TBI in Mantle Cell Lymphoma Patients?

P. Chevallier, M. Mohty, P. Moreau, 2012, Transplantation.

Analysis of platelet recovery after autologous transplantation with G-CSF mobilized CD34+ cells purified from leukapheresis products.

R. Bataille, S. Hermouet, B. Mahé, 1997, Hematology and cell therapy.

G‐CSF alone mobilizes sufficient peripheral blood CD34+ cells for positive selection in newly diagnosed patients with myeloma and lymphoma

R. Bataille, P. Moreau, S. Hermouet, 1996, British journal of haematology.

P135 Has treatment with EPO+/-G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database

H. Dombret, P. Greenberg, P. Fenaux, 2007 .

A non‐randomised dose‐escalating phase II study of thalidomide for the treatment of patients with low‐risk myelodysplastic syndromes: the Thal‐SMD‐2000 trial of the Groupe Français des Myélodysplasies

P. Fenaux, M. Tulliez, A. Moreau, 2005, British journal of haematology.

Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.

A. Stamatoullas, A. Vekhoff, B. Quesnel, 2009, Leukemia research.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: Final analysis of the GELA-GOELAMS FL2000 study with a 5-year follow-up

J. Rossi, G. Salles, R. Bouabdallah, 2007 .

Occurrence of a T cell lymphoma in a patient with chronic myeloid leukemia treated with alpha interferon.

P. Moreau, B. Mahé, N. Milpied, 1995, Leukemia & lymphoma.

Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation

P. Chevallier, M. Mohty, P. Moreau, 2011, Leukemia.

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

P. Chevallier, M. Béné, P. Moreau, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

FLT3 ligand plasma levels in acute myeloid leukemia

P. Chevallier, M. Béné, P. Moreau, 2019, Haematologica.

FLT 3 ligand plasma levels in acute myeloid leukemia

P. Chevallier, M. Béné, P. Moreau, 2019 .

A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

P. Chevallier, M. Béné, P. Moreau, 2020, Cancer medicine.

195 Autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes (MDS)

A. Stamatoullas, E. Solary, P. Fenaux, 1997 .

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

H. Dombret, A. Stamatoullas, L. Mannone, 2006 .

High dose radiochemotherapy followed by autologous stem cell transplantation in four patients with multiple lymphomatous polyposis

P. Moreau, A. Moreau, B. Mahé, 1995, Cancer.

Isolated Richter's syndrome of the brain: two recent cases.

P. Moreau, B. Mahé, S. Bourdin, 1994, Nouvelle revue francaise d'hematologie.

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia

M. Dimopoulos, C. Buske, S. Treon, 2018, The New England journal of medicine.

Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.

P. Feugier, S. Leprêtre, R. Letestu, 2017, The Lancet. Haematology.

Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.

O. Casasnovas, P. Feugier, S. Leprêtre, 2012, Blood.

Gamma heavy chain disease associated with large granular lymphocytic leukemia: A report of two cases and review of the literature

B. Mahé, A. Néel, F. Perrin, 2015, Hematology.

Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience

P. Chevallier, P. Moreau, C. Touzeau, 2020, Bone Marrow Transplantation.

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

P. Moreau, C. Touzeau, B. Mahé, 2019, Annals of Hematology.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study

P. Chevallier, P. Moreau, C. Touzeau, 2019, Annals of Hematology.

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14)

M. Amiot, P. Moreau, C. Touzeau, 2017, Haematologica.

Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.

P. Chevallier, M. Mohty, P. Moreau, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

P. Chevallier, P. Moreau, C. Touzeau, 2018, Leukemia research reports.

Lack of benefit of CD34+ cell selected over non-selected peripheral blood stem cell transplantation in multiple myeloma: results of a single center study

R. Bataille, P. Moreau, B. Mahé, 2000, Leukemia.

Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study

F. Bosch, R. Foà, S. Stilgenbauer, 2021, British journal of haematology.

Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia

L. Oliver, F. Vallette, B. Mahé, 2002, British journal of haematology.

Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required.

P. Chevallier, P. Moreau, B. Mahé, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High efficacy with five days schedule of oral fludarabine phosphate and cyclophosphamide in patients with previously untreated chronic lymphocytic leukaemia

P. Feugier, S. Leprêtre, B. Grosbois, 2008, British journal of haematology.

Melphalan 220 mg/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma

R. Bataille, P. Moreau, B. Mahé, 1999, Bone Marrow Transplantation.

A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity

R. Bataille, P. Moreau, B. Mahé, 1996, British journal of haematology.

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced‐intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo‐SCT)

P. Chevallier, M. Mohty, P. Moreau, 2013, European journal of haematology.

Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant

P. Chevallier, M. Béné, P. Moreau, 2021, British journal of haematology.

A 4 or 5 Deauville score assessed by (18)F-FDG-PET CT early post-allotransplant is highly predictive of relapse in lymphoma patients.

P. Chevallier, M. Béné, P. Moreau, 2018 .

A fixed-duration, measurable residual disease-guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial.

G. Salles, B. Pégourié, P. Feugier, 2020, Blood.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.

G. Salles, B. Pégourié, P. Feugier, 2019, The Lancet. Haematology.

Response to rituximab in B-CLL patients is adversely impacted by frequency of IL-10 competent B cells and FcγRIIIa polymorphism. A study of FCGCLL/WM and GOELAMS groups

P. Feugier, S. Leprêtre, V. Gouilleux-Gruart, 2016, Blood Cancer Journal.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

R. Bouabdallah, M. Hallek, V. Leblond, 2014, Blood.

Infectious complications after unrelated umbilical cord blood transplantation in adult patients with hematologic malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy

P. Chevallier, M. Béné, P. Moreau, 2021, British journal of haematology.

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

P. Chevallier, M. Mohty, P. Moreau, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

CD38 expression and secondary 17p deletion are important  prognostic factors in chronic lymphocytic leukaemia

R. Bataille, P. Chevallier, P. Moreau, 2002, British journal of haematology.

Prolonged PFS after Autologous Stem Cell Transplantation in Follicular Lymphoma Patients: A Long-Term Retrospective Study.

P. Moreau, L. Planche, B. Mahé, 2008 .

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).

S. Leprêtre, S. Kremer, L. Fornecker, 2015, Haematologica.

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.

P. Moreau, C. Touzeau, B. Mahé, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Reliable one-step assessment of IGHV mutational status and gene mutations in Chronic Lymphocytic Leukemia by capture-based high throughput sequencing

M. Béné, B. Mahé, F. Thonier, 2022, bioRxiv.

Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial

P. Feugier, M. Béné, C. Ferrand, 2012, Bone Marrow Transplantation.

PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma

P. Moreau, B. Mahé, N. Milpied, 2003, Bone Marrow Transplantation.

High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience

P. Moreau, B. Mahé, N. Milpied, 1998, Bone Marrow Transplantation.

Factors predicting allogeneic PBSCs yield after G-CSF treatment in healthy donors

P. Chevallier, M. Mohty, P. Moreau, 2009, Bone Marrow Transplantation.

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study

Pierre-Yves Dumas, Dominique Bordessoule, Fabrice Jardin, 2016, American journal of hematology.

Ex vivo expansion of hematopoietic progenitors from CD34+ cells selected from leukapheresis products of lymphoma and myeloma patients: feasibility and enhancement by fibronectin.

S. Hermouet, B. Mahé, N. Robillard, 1996, Journal of hematotherapy.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

P. Chevallier, M. Mohty, P. Moreau, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Complete Donor T-Cell Chimerism Predicts Lower Relapse Incidence after Standard Double Umbilical Cord Blood Reduced Intensity Conditioning Regimen Allogeneic Transplantation in Adults

P. Chevallier, M. Mohty, P. Moreau, 2014 .

HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells.

L. Oliver, F. Vallette, P. Juin, 2007, Leukemia research.

Relapsed or refractory chronic lymphocytic leukemia retreated with rituximab in daily practice: final results of the PERLE study

S. Leprêtre, A. Delmer, S. Choquet, 2019, Leukemia & lymphoma.

Bendamustine, Ofatumumab and High-Dose Methylprednisolone (BOMP) in Relapsed/Refractory CLL: Results of a Planned Interim Analysis of the French CLL Intergroup ICLL01 Phase II Trial

P. Feugier, S. Leprêtre, A. Schuh, 2014 .

Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.

P. Chevallier, M. Mohty, P. Moreau, 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Successful allogeneic bone marrow transplantation for early relapse after autologous bone marrow transplantation in two cases of aggressive high-grade non-Hodgkin's lymphoma.

P. Moreau, B. Mahé, N. Milpied, 1996, Bone marrow transplantation.

Prophylaxis with mycophenolate mofetil and CsA can decrease the incidence of severe acute GVHD after antithymocyte globulin-based reduced-intensity preparative regimen and allo-SCT from HLA-matched unrelated donors

P. Chevallier, M. Mohty, P. Moreau, 2010, Bone Marrow Transplantation.

[Eruptive xanthogranulomatosis in a trisomy 21 patient with acute lymphoblastic leukemia].

B. Mahé, J. Stalder, E. Cassagnau, 2000, Annales de dermatologie et de vénéréologie.

Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier

P. Chevallier, M. Béné, P. Moreau, 2017, Bone Marrow Transplantation.

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

E. Kimby, C. Buske, J. Dreyhaupt, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study

M. Dimopoulos, C. Buske, S. Treon, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fludarabine Plus Cyclophosphamide and Rituximab (RFC) in Waldenström’s Macroglobulinemia (WM): Results in 21 Patients (pts).

V. Leblond, S. Choquet, B. Mahé, 2006 .

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

O. Casasnovas, S. Leprêtre, S. Chevret, 2019, Blood.

Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study

M. Dimopoulos, C. Buske, S. Treon, 2018, Blood.

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

P. Chevallier, M. Mohty, M. Béné, 2017, European journal of haematology.

Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma

M. Mohty, P. Moreau, B. Mahé, 2012, Leukemia.

Fludarabine Plus Cyclophosphamide and Rituximab In Waldenström's Macroglobulinemia: Results In 55 Patients

J. Tamburini, C. Gardin, A. Delmer, 2010 .

Infections Cryptococcus neoformans dans les hmopathies malignes

B. Mahé, N. Milpied, J. Harousseau, 2000 .

Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM Study

M. Dimopoulos, C. Buske, S. Treon, 2020 .

Lung Resection for Invasive Pulmonary Aspergillosis in Neutropenic Patients with Hematologic Malignancies: Long Term Results in Thirty Two Cases.

P. Moreau, C. Touzeau, J. Delaunay, 2006 .

Bortezomib in Combination with Dexamethasone, Rituximab and Cyclophosphamide (B-DRC) As First – Line Treatment of Waldenstrom’s Macroglobulinemia: Results of a Prospectively Randomized Multicenter European Phase II Trial

E. Kimby, M. Dimopoulos, C. Buske, 2020 .

Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma

P. Chevallier, M. Mohty, P. Moreau, 2010, Leukemia & lymphoma.

S. Leprêtre, M. Béné, F. Davi, 2022, HemaSphere.

A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.

B. Pégourié, G. Mufti, D. Oscier, 1996, Blood.

Antithymocyte globulin administration in patients with profound lymphopenia receiving a PBSC purine analog/busulfan-based conditioning regimen allograft

P. Chevallier, M. Béné, P. Moreau, 2020, Scientific Reports.

Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia

O. Casasnovas, P. Feugier, S. Leprêtre, 2018, Haematologica.

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies

P. Chevallier, M. Béné, P. Moreau, 2018, Oncotarget.

Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma

M. Mohty, P. Moreau, L. Planche, 2012, Leukemia & lymphoma.

B Cell Aplasia Is the Most Powerful Predictive Marker for Poor Humoral Response after BNT162b2 mRNA SARS-CoV-2 Vaccination in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

P. Chevallier, M. Rimbert, M. Béné, 2022, Transplantation and Cellular Therapy.

Safety and efficacy of rituximab in steroid-refractory chronic GVHD

P. Chevallier, M. Mohty, P. Moreau, 2013, Bone Marrow Transplantation.

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

P. Chevallier, P. Moreau, C. Leux, 2020, Annals of Hematology.

Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death.

P. Moreau, C. Leux, A. Moreau, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Positive Impact of Iron Chelation Therapy (CT) on Survival in Regularly Transfused MDS Patients. A Prospective Analysis by the GFM.

A. Stamatoullas, B. Quesnel, P. Fenaux, 2007 .

Thalidomide for the Treatment of Low Risk Myelodysplasia.

A. Stamatoullas, P. Fenaux, A. Aouba, 2004 .

Autologous bone marrow transplantation using TBI and CBV for disseminated high/intermediate grade cutaneous non-epidermotropic non-Hodgkin's lymphoma.

P. Moreau, A. Moreau, M. Mahé, 1994, Bone marrow transplantation.

Patient-reported outcomes (PROs) with ibrutinib-rituximab in Waldenström macroglobulinemia (WM): Results from iNNOVATE.

M. Dimopoulos, C. Buske, D. Macdonald, 2019, Journal of Clinical Oncology.

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

P. Chevallier, M. Béné, P. Moreau, 2021, EJHaem.

Autologous bone marrow transplantation for cyclosporin-related lymphoma in a renal transplant patient.

P. Moreau, B. Mahé, N. Milpied, 1994, Bone marrow transplantation.

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

P. Feugier, S. Leprêtre, R. Letestu, 2023, Blood advances.

Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no‐treatment study

R. Porcher, F. Jardin, M. Mohty, 2016, American journal of hematology.

Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.

J. Rossi, G. Salles, R. Bouabdallah, 2008, Blood.

Long‐term outcome of monoclonal (type 1) cryoglobulinemia

B. Grosbois, O. Decaux, P. Moreau, 2014, American journal of hematology.

Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.

P. Chevallier, C. Touzeau, B. Mahé, 2024, American journal of hematology.

High-dose melphalan is not associated with extramedullary relapses in high-risk multiple myeloma.

R. Bataille, P. Moreau, B. Mahé, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.